- 1、本文档共35页,可阅读全部内容。
- 2、原创力文档(book118)网站文档一经付费(服务费),不意味着购买了该文档的版权,仅供个人/单位学习、研究之用,不得用于商业用途,未经授权,严禁复制、发行、汇编、翻译或者网络传播等,侵权必究。
- 3、本站所有内容均由合作方或网友上传,本站不对文档的完整性、权威性及其观点立场正确性做任何保证或承诺!文档内容仅供研究参考,付费前请自行鉴别。如您付费,意味着您自己接受本站规则且自行承担风险,本站不退款、不进行额外附加服务;查看《如何避免下载的几个坑》。如果您已付费下载过本站文档,您可以点击 这里二次下载。
- 4、如文档侵犯商业秘密、侵犯著作权、侵犯人身权等,请点击“版权申诉”(推荐),也可以打举报电话:400-050-0827(电话支持时间:9:00-18:30)。
查看更多
Investor science conference
call: American Society of
Clinical Oncology
Genitourinary (ASCO GU)
Cancers Symposium 2022
Conference call for investors and analysts
23 February 2022
Forward-looking statements
In order, among other things, to utilise the safe harbour provisions of the US Private Securities Litigation Reform Act of 1995, AstraZeneca (hereafter ‘the Group’) provides the
following cautionary statement: this document contains certain forward-looking statements with respect to the operations, performance and financial condition of the Group,
including, among other things, statements about expected revenues, margins, earnings per share or other financial or other measures. Although the Group believes its expectations
are based on reasonable assumptions, any forward-looking statements, by their very nature, involve risks and uncertainties and may be influenced by factors that could cause actual
outcomes and results to be materially different from those predicted. The forward-looking statements reflect knowledge and information available at the date of preparation of this
document and the Group undertakes no obligation to update these forward-looking statements. The Group identifies the forward-looking statements by using the words
anticipates, believes, expects, intends and similar expressions in such statements. Important factors that could cause actual results to differ materially from those contained in
forward-looking statements, certain of which are beyond the Group’s control, include, among other things : the risk of failure or delay in delivery of pipeline or launch of new
medicines; the risk of failure to meet regulatory or ethical requirements for medicine development or approval; the risk of failure to obtain, defend and enforce effective IP
protection and IP challenges by third parties; the impac
您可能关注的文档
- 2022年第38届几何学计算国际研讨会(会议论文合集).pdf
- 2022年第49届EATCS自动机、语言和编程国际会议(会议论文合集).pdf
- 经济事务研究所-碳难题:如何从政府失败中拯救气候变化政策(英)-2022.8.pdf
- 2022年全球项目风险报告.pdf
- 2022年施工风险管理报告.pdf
- 2022施耐德电气铁路云峰会:绿色、智能——施耐德电气创新未来开关设备.pdf
- EY 上市指南:上市前、上市中和上市后的战略考虑.pdf
- SAP 如何通过数字化转型提升采购部门的价值(中文).pdf
- 阿斯利康 2022美国临床肿瘤学会年度会议演示资料.pdf
- 百时美施贵宝 疾病状态信息图表合集.pdf
- 专卖店促销员销售与成交技巧培训课件(34P).pptx
- 红色商务风新员工入职销售技巧知识培训课件(34P).pptx
- 专卖店商场销售员销售与成交技巧培训课件(34P).pptx
- 小区物业保安法律知识培训课件(28P).pptx
- 专卖店销售员轻松成交技巧培训(34P).pptx
- 轻松成交客户新员工入职通用销售技巧知识培训(34P).pptx
- 2024年初级《银行业法律法规与综合能力》考前必刷必练题库500题(含真题、必会题).docx
- 2024年“新安法知多少”知识竞赛题库及答案(最新版).docx
- 2024年30秒毕业生面试工作自我介绍.docx
- 2024年《医务人员礼仪培训》心得体会.docx
文档评论(0)